NEW YORK (GenomeWeb) – Fluidigm today announced an approximately 19 percent decline in total revenue for the fourth quarter of 2016, among other preliminary financial results.

For the three months ended Dec. 31, the South San Francisco instrumentation firm expects between $24.7 million and $25.2 million in revenues, down from $30.7 million a year ago. On average, analysts are expecting total Q4 revenues of $26.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.